CINV

Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs

Retrieved on: 
Monday, June 12, 2023
Palonosetron, Nausea, FACP, Agency for Healthcare Research and Quality, CINV, Antiemetic, Advances in Therapy, APPA, Pharmacy, Doctor of Philosophy, Quality, GLM, Vomiting, Cancer, MD, Patient, Data, Agency, Lead author, Rare, Pharmaceutical industry, Health insurance, Pet industry, Hospital

The dataset provides insight to nearly 80% of the US healthcare system, with patient-level data from all provider types.

Key Points: 
  • The dataset provides insight to nearly 80% of the US healthcare system, with patient-level data from all provider types.
  • Referring to the details of the publication below, these real-world data showed that healthcare resource utilization, such as CINV-related visits were significantly lower after AKYNZEO® compared to fosaprepitant/palonosetron (APPA).
  • CINV-related healthcare costs were also statistically and/or numerically lower for patients receiving AKYZNEO® compared to APPA.
  • There remains a gap between expected and actual patient outcomes as clinicians translate trial data and clinical guidelines into practice.

Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs

Retrieved on: 
Friday, February 3, 2023
Vomiting, Palonosetron, Future Oncology, CINV, Nausea, Hospital, APON, Patient, Use, APPA, Precision medicine, NEPA, Degenerative disease, Research, Ondansetron, Medical imaging

The article, “Antiemetic Use and Chemotherapy Induced Nausea and Vomiting related Hospitalization Costs After Highly or Moderately Emetogenic Chemotherapy”, evaluates the effect of NEPA on chemotherapy-induced nausea and vomiting (CINV)-related hospitalization costs.

Key Points: 
  • The article, “Antiemetic Use and Chemotherapy Induced Nausea and Vomiting related Hospitalization Costs After Highly or Moderately Emetogenic Chemotherapy”, evaluates the effect of NEPA on chemotherapy-induced nausea and vomiting (CINV)-related hospitalization costs.
  • NEPA was compared to aprepitant/fosaprepitant-containing regimens among patients who received highly or moderately emetogenic chemotherapy in the US.
  • The study findings suggest that the downstream economic impact of antiemetic choice may differ depending on the combination of treatments.
  • Hospitalizations with CINV as the primary reason for admission were identified and all incurred costs for these hospital stays were used in the cost accounting.

Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets

Retrieved on: 
Tuesday, January 24, 2023
Vomiting, CINV, Quality of life, Netupitant/palonosetron, Patient, Partnership, Degenerative disease, Pharmaceutical industry, Palonosetron

Under the licence and distribution agreement Immedica will commercialise AKYNZEO® in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg and Liechtenstein, ALOXI® in Switzerland, Belgium, Liechtenstein.

Key Points: 
  • Under the licence and distribution agreement Immedica will commercialise AKYNZEO® in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg and Liechtenstein, ALOXI® in Switzerland, Belgium, Liechtenstein.
  • Anders Edvell, CEO of Immedica commented: “We are very pleased to have signed this agreement with Helsinn.
  • Side-effects of cancer treatments have a significant impact on the quality of life of these severely ill patients.
  • We look forward to working closely with Immedica in the months and years ahead to ensure more and more patients can access these important supportive care products.”

Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises

Retrieved on: 
Monday, January 9, 2023
Food, Therapy, Aprepitant, Regulation of tobacco by the U.S. Food and Drug Administration, Vomiting, SAN, Elective surgery, Shanda, PONV, Patient, Growth, FDA, Heron, Pharming, CMS, New Drug Application, CINV, Beauty salon, Pharmaceutical industry, Video game

SAN DIEGO, Jan. 9, 2023 /PRNewswire/ --Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today highlights progress in its acute care and oncology care franchises.

Key Points: 
  • Full-Year 2022 Net Product Sales: Preliminary full-year 2022 net product sales for ZYNRELEF were approximately $10.1 million.
  • Fourth-Quarter 2022 Net Product Sales: Preliminary fourth-quarter 2022 net product sales for the oncology care franchise were approximately $25.3 million.
  • Full-Year 2022 Net Product Sales: Preliminary full-year 2022 net product sales for the oncology care franchise were approximately $96.6 million versus guidance of $93 million to $95 million.
  • Full-Year 2023 Net Product Sales Guidance: Heron expects full-year 2023 net product sales for the oncology care franchise of $99 million to $103 million.

Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV

Retrieved on: 
Wednesday, January 4, 2023
Radiation oncologist, Patient, Oncology, IV, Degenerative disease, Vomiting, CR, Risk, CINV, Pharmaceutical industry

Using data from a previously reported phase 3 trial, the analysis classified patients into 3 groups based on their response during the first chemotherapy cycle: CR, short-term CINV (1-2 days), and extended CINV (3-5 days).

Key Points: 
  • Using data from a previously reported phase 3 trial, the analysis classified patients into 3 groups based on their response during the first chemotherapy cycle: CR, short-term CINV (1-2 days), and extended CINV (3-5 days).
  • The analysis indicated that patients who experienced CR in their first cycle had a 93% or higher CR rates in subsequent cycles.
  • Comparing patients with short-term CINV and extended CINV in cycle 1, recurrent CINV occurred in 30.6% and 69.5% of subsequent cycles, respectively (p
  • With close monitoring during the first chemotherapy cycle, clinicians can use the patient’s response data to optimize antiemetic prophylaxis when extended CINV does occur.

REDUVO™ Marketing Approval on the Right Path

Retrieved on: 
Thursday, December 22, 2022
Tetra, Patient, Vomiting, Plasma protein binding, NDS, Health Canada, Weight loss, TSX, Insurance, TBP, Dronabinol, FRA, FDA, THC, Inflammation, Safety, Risk management plan, Risk management, HIV/AIDS, News, HIV, Multimedia, Cannabis, CINV, Pain, Nausea, Legislation, Physician, Research, Pharmaceutical industry

The Company will be submitting the response to Health Canada within the allowed timeframe.

Key Points: 
  • The Company will be submitting the response to Health Canada within the allowed timeframe.
  • Questions/feedback from Health Canada are received as the review of the dossier progresses through different review streams.
  • It is also used to treat weight loss and severe nausea in people living with HIV infection.
  • The active pharmaceutical ingredient in REDUVO™ is dronabinol, also known as THC, a synthetic form of the active natural substance in cannabis.

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia

Retrieved on: 
Tuesday, November 29, 2022
National Comprehensive Cancer Network, Liver, Degenerative disease, Kidney, Risk, Benzodiazepine, Medical Affairs Bureau, Chronic kidney disease, Serotonin syndrome, Therapy, Alprazolam, DEX, Dexamethasone, Patient, Heart, Environment, Palonosetron, Nausea, Hypersensitivity, Journal of the National Comprehensive Cancer Network, Fatigue, Respect, European Society for Medical Oncology, CINV, MEC, Constipation, Seizure, Plasma, Growth, NCCN, Weakness, University, Oncology, Capsule, Antiemetic, Midazolam, Netupitant, NEPA, Licensed practical nurse, Triazolam, Headache, Anaphylaxis, Indigestion, Erythema, ESMO, Cancer, Dysautonomia, Congress, Pharmaceutical industry, Platinum, Vaccine, CYP3A4, Vomiting

Lugano, Switzerland, November 29, 2022 - Helsinn Group (Helsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December.

Key Points: 
  • Lugano, Switzerland, November 29, 2022 - Helsinn Group (Helsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December.
  • Full details of the poster presentation are below:
    Dr Silvia Sebastiani, Helsinn Group Head of Medical Affairs, commented: We are pleased to present the design of this important ongoing study at the ESMO Asia congress.
  • Despite the array of effective antiemetics, CINV still represents a huge unmet need in clinical practice.
  • Available at: http://www.mascc.org/ /
    2 NCCN: National Comprehensive Cancer Network; NCCN Clinical Practice Guidelines in Oncology; Version 2.2022.

Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region

Retrieved on: 
Monday, November 28, 2022
Marketing, Arbutus Biopharma, Humanitarian use licenses, Dexamethasone, Heart, Growth, Environment, Degenerative disease, Nausea, Patient, Respect, Vomiting, Emerging market, Cancer, CINV, Therapy, Quality of life, The Farm (franchise), Pharmaceutical industry, Baltic

Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO in Estonia and Latvia.

Key Points: 
  • Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO in Estonia and Latvia.
  • Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented: This agreement once again demonstrates the Farma Mondos mission to provide access to medicines where no one else can.
  • We are proud to partner with Helsinn in the Baltic region as we continue to expand our infrastructure worldwide to further support patients unmet needs.
  • For more information about Farma Mondo please visit: www.farmamondo.com
    Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland.

Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission

Retrieved on: 
Friday, November 18, 2022
Tetra, Plasma protein binding, Vomiting, TSX, Pain, CINV, NDS, Dronabinol, Cannabis, News, Legislation, Physician, HIV/AIDS, Health Canada, Safety, THC, FDA, Weight loss, HIV, Insurance, Research, Multimedia, Patient, FRA, Inflammation, TBP, Nausea, Pharmaceutical industry

MONTREAL, Nov. 18, 2022 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO New Drug Submission (NDS).

Key Points: 
  • MONTREAL, Nov. 18, 2022 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO New Drug Submission (NDS).
  • On December 30, 2020, the Company submitted its first new drug submission ("NDS") for the REDUVO soft gel capsules to Health Canada to obtain approval and a drug identification number ("DIN") for the prescription drug.
  • On November 16, the Company received a Clarification Request (Clarifax) from Health Canada regarding the product labels.
  • The active pharmaceutical ingredient in REDUVO is dronabinol, also known as THC, a synthetic form of the active natural substance in cannabis.

Crucial Innovations Corp. (OTC: CINV), Announces Completion of Reverse Merger with Eco Equity, Medical Cannabis operator in Zimbabwe, Africa

Retrieved on: 
Wednesday, October 26, 2022
CINV, SEC, Glass, SEC filing, Securities Exchange Act of 1934, Acquisition, ECO, Medical cannabis, Securities Act of 1933, Safe harbor, The O.C., Guernsey, OTC, Nature, Research, GLOBE, USD, Investment, Cannabis, Genetics, Access to Cannabis for Medical Purposes Regulations, Security (finance), Drug, Cannabinoid

The completion of the reverse takeover of CINV by Eco Equity Zimbabwe means Eco Equity Pty Limited Zimbabwe is now a wholly owned subsidiary of the publicly traded company CINV.

Key Points: 
  • The completion of the reverse takeover of CINV by Eco Equity Zimbabwe means Eco Equity Pty Limited Zimbabwe is now a wholly owned subsidiary of the publicly traded company CINV.
  • This is an important milestone in the evolution of Eco Equity and the increasingly global cannabis industry, said JP Doran, JPDs co-founder and chief executive.
  • "The reverse merger gives us the opportunity to accelerate our growth trajectory and will enable us to cement our position as one of the most progressive Cannabis companies globally.
  • This material contains statements about expected future events and/or financial results that are forward-looking in nature and as such are by definition subject to risks and uncertainties